From each FDA label

Do GLP-1s cause vomiting?

Vomiting is in the main trial table of 9 labels. The highest rate printed is 24% on Foundayo 17.2 mg (4% on placebo) and the lowest 8% on Rybelsus and Ozempic tablets 14 mg (3% on placebo). Separate trials, so not a ranking. Byetta lists it only among reports after approval, without a rate.

Read from each manufacturer's FDA label on DailyMed. The newest revision saying anything on this is Aug 28, 2026.

Rate against placebo

How often vomiting happened in each medicine's trials

At the highest dose in each label's main table. Separate trials with different people, so compare each rate with its own placebo group, not with another medicine.

MedicineDoseOn itOn placeboDifferenceLabel
Foundayo17.2 mg24%4%+20 pointsDailyMed
Wegovy2.4 mg24%6%+18 pointsDailyMed
Saxenda3 mg15.7%3.9%+11.8 pointsDailyMed
Zepbound15 mg13%2%+11 pointsDailyMed
Trulicity1.5 mg12.7%2.3%+10.4 pointsDailyMed
Ozempic1 mg9.2%2.3%+6.9 pointsDailyMed
Mounjaro15 mg9%2%+7 pointsDailyMed
Victoza1.8 mg9%2%+7 pointsDailyMed
Rybelsus and Ozempic tablets14 mg8%3%+5 pointsDailyMed
Word for word

What each label says about vomiting

Sentences from each label's warnings and side effect sections. Only cross-references are removed.

Wegovy

  • The most common adverse reactions leading to discontinuation were nausea (1.8% versus 0.2%), vomiting (1.2% versus 0%), and diarrhea (0.7% versus 0.1%) for Wegovy and placebo, respectively.
  • In clinical trials in adults for weight reduction, 73% of Wegovy injection-treated patients and 47% of patients receiving placebo reported gastrointestinal adverse reactions, including severe reactions that were reported more frequently among patients receiving Wegovy injection (4.1%) than placebo (0.9%). The most frequently reported reactions were nausea (44% vs. 16%), vomiting (25% vs. 6%), and diarrhea (30% vs. 16%).
  • In the pediatric clinical trial for weight reduction, 62% of Wegovy injection-treated patients and 42% of placebo-treated patients reported gastrointestinal adverse reactions. The most frequently reported reactions were nausea (42% vs. 18%), vomiting (36% vs. 10%), and diarrhea (22% vs. 19%).

Label revised Jun 18, 2026. DailyMed

Ozempic

  • The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation.

Label revised Jun 1, 2026. DailyMed

Zepbound

  • The majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time.

Label revised Aug 28, 2026. DailyMed

Mounjaro

  • In a CV outcomes trial of 6,647 adults with type 2 diabetes mellitus and established CV disease exposed to Mounjaro, adverse reactions reported with Mounjaro were similar with the exception of dysesthesia (0.7%), decreased appetite (17%), constipation (13%), vomiting (12%), abdominal pain (10%), and fatigue (10%).
  • The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation and decreased over time.
  • The incidences of adverse reactions reported in pediatric patients treated with Mounjaro 5 mg and 10 mg subcutaneously once-weekly were consistent with those described above for adult patients with type 2 diabetes mellitus with the exception of a higher incidence of vomiting, abdominal pain, and hypoglycemia.
  • During the 30-week placebo-controlled period of the study, vomiting occurred in 3%, 16%, and 12% of patients and abdominal pain occurred in 9%, 22%, and 15% of patients treated with placebo, Mounjaro 5 mg, and 10 mg, respectively.

Label revised Aug 27, 2026. DailyMed

Foundayo

  • The incidence of nausea, vomiting, and diarrhea was higher during the Foundayo dosage escalation period and decreased over time.

Label revised Jul 29, 2026. DailyMed

Saxenda

  • The most common adverse reactions leading to discontinuation were nausea (2.9% versus 0.2% for Saxenda and placebo, respectively), vomiting (1.7% versus less than 0.1%), and diarrhea (1.4% versus 0%).
  • There have been reports of gastrointestinal adverse reactions, such as nausea, vomiting, and diarrhea, associated with volume depletion and renal impairment.
  • Most adverse reactions leading to discontinuation were due to vomiting and nausea (4.8% and 3.2% of Saxenda-treated patients, respectively).
  • Events of asthenia, fatigue, malaise, dysgeusia and dizziness were mainly reported within the first 12 weeks of treatment with Saxenda and were often co-reported with gastrointestinal events such as nausea, vomiting, and diarrhea.

Label revised Feb 25, 2026. DailyMed

Byetta

  • The most common adverse reactions leading to withdrawal for Byetta-treated patients were nausea (3% of patients) and vomiting (1%).
  • For placebo-treated patients, <1% withdrew due to nausea and none due to vomiting.
  • The most common adverse reactions leading to withdrawal for Byetta-treated patients were nausea (9%) and vomiting (5%).
  • The most frequently reported adverse reactions leading to withdrawal for Byetta-treated patients were nausea (5.1%) and vomiting (2.9%).

Label revised Sep 2, 2025. DailyMed

Victoza: listed only among reports after approval, which come with no rate because nobody knows how many people took the medicine. Trulicity: no finding on this in the sections read here.

Not from trials

Reports to FDA about vomiting

Counts of voluntary reports from patients and doctors. They cannot show that a medicine caused anything and cannot give a rate, and a brand used by more people draws more reports.

MedicineReports namingAll reports on it
OzempicVomiting: 6,68170,863
TrulicityVomiting: 5,81387,279
MounjaroVomiting: 5,17997,440
ByettaVomiting: 4,32752,087
ZepboundVomiting: 3,89580,835
VictozaVomiting: 2,89641,462
WegovyVomiting: 2,19825,993
Rybelsus and Ozempic tabletsVomiting: 7707,758
SaxendaVomiting: 6307,270
FoundayoVomiting: 2823,050

Counted through openFDA from FDA's Adverse Event Reporting System, refreshed weekly. One report can name several terms.

Updated automatically

Latest FDA label updates

Written from each source's own record as it changes. Every change on GLPcompare

Questions

Vomiting on a GLP-1: common questions

Which GLP-1 causes the most vomiting?

No trial here ranks them. By the rates each label prints, Foundayo 17.2 mg is highest at 24% (placebo 4%) and Rybelsus and Ozempic tablets 14 mg lowest at 8% (placebo 3%). These come from separate trials with different people and doses, so compare each to its own placebo group.

Does Foundayo cause vomiting?

In its FDA label, 24% of people taking Foundayo 17.2 mg reported vomiting, against 4% on placebo.

Does Wegovy cause vomiting?

In its FDA label, 24% of people taking Wegovy 2.4 mg reported vomiting, against 6% on placebo.

Does Saxenda cause vomiting?

In its FDA label, 15.7% of people taking Saxenda 3 mg reported vomiting, against 3.9% on placebo.

Does Zepbound cause vomiting?

In its FDA label, 13% of people taking Zepbound 15 mg reported vomiting, against 2% on placebo.

Does Trulicity cause vomiting?

In its FDA label, 12.7% of people taking Trulicity 1.5 mg reported vomiting, against 2.3% on placebo.

Does Ozempic cause vomiting?

In its FDA label, 9.2% of people taking Ozempic 1 mg reported vomiting, against 2.3% on placebo.

How long does vomiting last on a GLP-1?

Labels describe when it happens, not how many days it lasts. Ozempic: "The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation." Rybelsus and Ozempic tablets: "The majority of reports of nausea, vomiting and/or diarrhea occurred during dose escalation." Zepbound: "The majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time."

Other side effects

Trial rates describe groups, not what one person will feel. Talk to your clinician before starting, stopping or changing a medicine.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.